Insulin-like growth factor 1 receptor inhibitors: Where do we come from? What are we? Where are we going?

E-ISSN： 1097-0142|120|16|2384-2387

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.16, 2014-08, pp. : 2384-2387

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Personalized medicine in oncology: where have we come from and where are we going?

By André Fabrice Ciccolini Joseph Spano Jean-Philippe Penault-Llorca Frédérique Mounier Nicolas Freyer Gilles Blay Jean-Yves Milano Gérard

Pharmacogenomics, Vol. 14, Iss. 8, 2013-06 ,pp. : 931-939

Future Medicine

Access to resources Recommend Favorite

Tuberculosis: where are we going?

By Thwaites Guy

Clinical Medicine, Vol. 6, Iss. 6, 2006-12 ,pp. : 523-525

Royal College Of Physicians

Access to resources Recommend Favorite

Paediatric Pharmacy in Australia: Where Have We Come From and Where Do We Need To Go?

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 43, Iss. 1, 2013-03 ,pp. : 45-48

John Wiley & Sons Inc

Access to resources Recommend Favorite

Protease inhibitors - where do we stand?

By Neumann U.

Trends in Pharmacological Sciences, Vol. 23, Iss. 8, 2002-08 ,pp. : 394-394

Elsevier

Access to resources Recommend Favorite

Chronic lymphocytic leukemia: where are we and where are we going?

By Ujjani Chaitra Cheson Bruce D

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 12, 2012-08 ,pp. : 1675-1677

Informa Healthcare

Access to resources Recommend Favorite